What's New with Roche Pathology Lab

We are personally committed to driving diagnostic certainty for life-changing decisions in pathology. We do this by advancing science to help improve patients’ lives and by delivering innovative solutions that break down the barriers that anatomic pathology labs face every day. This empowers our customers to reach their full potential now, and build a future that holds the potential to beat cancer.

2025 Tissue Diagnostics Product Catalog

Like you, we’re passionate about the patient behind every slide. We’re committed to transforming cancer diagnosis with solutions that address the needs of anatomic pathology labs and healthcare professionals to help them improve the lives of the patients they serve. Our broad portfolio includes VENTANA integrated staining and workflow management platforms, digital pathology solutions and a robust menu of high-medical value assays that help labs increase efficiency, improve patient safety and deliver medical value.

HER2-ultralow

PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody is now FDA-approved for patients with HER2-ultralow levels of expression who may benefit from targeted treatment.

Roche Digital Pathology Dx

The Roche Digital Pathology solution combines innovative hardware, software and uPath image analysis software for greater efficiency and earlier diagnosis.

MMR Predictive dMMR

Provide multiple therapy options with one MMR CDx IHC panel.

Kappa Lambda Dual ISH

Roche announced today FDA approval of Alecensa^® (alectinib) for adjuvant treatment following tumour resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumours ≥ 4 cm or node positive), as detected by an FDA-approved test.

IVD

INSM1 (SP493)

INSM1 (SP493) Rabbit Monoclonal Primary Antibody is intended for laboratory use in the qualitative immunohistochemical detection of INSM1 protein by light microscopy in sections of formalin-fixed, paraffinembedded tissue stained on a BenchMark IHC/ISH instrument.

Advancing Diagnostic Certainty in Biliary Tract Cancers (BTC)

Innovative HER2 testing is elevating hope for patients with Biliary Tract Cancer (BTC) that has progressed after first-line therapy. There is a significant unmet need for targeted therapies that can potentially improve survival.

IVD

CD68 (SP251v18)

CD68 (SP251v18) Rabbit Monoclonal Antibody is intended for laboratory use in the qualitative immunohistochemical detection of CD68 by light microscopy in sections of formalin -fixed, paraffin- embedded tissue stained on a BenchMark IHC/ISH instrument.